Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 14/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571829 | 0.85 | GAA (0.44) | MTNR1AMTNR1BESR1ALDH1A1 | |
| SCHEMBL7879014 | 0.84 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL7869511 | 0.84 | TSHR (0.38) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL6136382 | 0.84 | MTNR1A (0.51) | MTNR1AMTNR1BESR1HSD17B2ALDH1A1 | |
| SCHEMBL7401203 | 0.81 | CACNA1F (0.41) | CACNA1FCACNA1DCACNA1SCACNA1CALDH1A1 | |
| SCHEMBL7404622 | 0.78 | TSHR (0.39) | ALDH1A1 | |
| SCHEMBL8812902 | 0.78 | MTNR1A (0.51) | MTNR1AMTNR1BHSD17B2 | |
| SCHEMBL7237747 | 0.76 | GAA (0.37) | CACNA1FCACNA1DCACNA1SCACNA1CALDH1A1 | |
| SCHEMBL7237657 | 0.76 | MEN1 (0.37) | ALDH1A1 | |
| SCHEMBL6448597 | 0.76 | SLC6A2 (0.40) | CACNA1FCACNA1DCACNA1SCACNA1CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153847-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-20050203080-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2005-09-15 | — | — | US | disclosed |
| EP-0951466-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998028268-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203080-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | MTNR1A 3275/4885MTNR1B 2307/4885ESR1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.